KR20160134719A - 신규한 다형체 및 신규한 고체 상태의 티아쿠미신 ｂ - Google Patents

신규한 다형체 및 신규한 고체 상태의 티아쿠미신 ｂ Download PDF

Info

Publication number
KR20160134719A
KR20160134719A KR1020167027975A KR20167027975A KR20160134719A KR 20160134719 A KR20160134719 A KR 20160134719A KR 1020167027975 A KR1020167027975 A KR 1020167027975A KR 20167027975 A KR20167027975 A KR 20167027975A KR 20160134719 A KR20160134719 A KR 20160134719A
Authority
KR
South Korea
Prior art keywords
solvate
tiacumicin
crystalline
xrpd
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167027975A
Other languages
English (en)
Korean (ko)
Inventor
슈테판 클루게
Original Assignee
셀리아 파마슈티칼즈 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀리아 파마슈티칼즈 에이피에스 filed Critical 셀리아 파마슈티칼즈 에이피에스
Publication of KR20160134719A publication Critical patent/KR20160134719A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
KR1020167027975A 2014-03-18 2015-03-17 신규한 다형체 및 신규한 고체 상태의 티아쿠미신 ｂ Ceased KR20160134719A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461954715P 2014-03-18 2014-03-18
US61/954,715 2014-03-18
US201462020570P 2014-07-03 2014-07-03
US62/020,570 2014-07-03
PCT/EP2015/055531 WO2015140153A1 (en) 2014-03-18 2015-03-17 New polymorphs and new solid states of tiacumicin b

Publications (1)

Publication Number Publication Date
KR20160134719A true KR20160134719A (ko) 2016-11-23

Family

ID=52697399

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167027975A Ceased KR20160134719A (ko) 2014-03-18 2015-03-17 신규한 다형체 및 신규한 고체 상태의 티아쿠미신 ｂ

Country Status (17)

Country Link
US (1) US10227371B2 (https=)
EP (1) EP3119793B1 (https=)
JP (1) JP2017507994A (https=)
KR (1) KR20160134719A (https=)
CN (1) CN106103462A (https=)
AU (1) AU2015233583B2 (https=)
BR (1) BR112016021542B1 (https=)
CA (1) CA2940902C (https=)
DK (1) DK3119793T3 (https=)
ES (1) ES2668351T3 (https=)
HR (1) HRP20180668T1 (https=)
HU (1) HUE038426T2 (https=)
IL (2) IL247726A0 (https=)
PL (1) PL3119793T3 (https=)
PT (1) PT3119793T (https=)
SI (1) SI3119793T1 (https=)
WO (1) WO2015140153A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108727387B (zh) * 2018-07-25 2021-03-16 天津大学 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法
CN109053738B (zh) * 2018-08-29 2020-10-16 浙江工业大学 一种依鲁替尼的溶剂化物及其制备方法
CN114224899B (zh) * 2020-09-09 2024-04-26 首都医科大学附属北京胸科医院 非达霉素用于制备抑制脓肿分枝杆菌活性的产品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
WO2004014295A2 (en) 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Tiacumicin production
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
CN102614207B (zh) * 2005-01-31 2016-01-13 默克夏普&多梅有限公司 18元环大环化合物及其类似物
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
ITMI20120560A1 (it) 2012-04-05 2013-10-06 Olon Spa Procedimento per la purificazione della tiacumicina b
US8722863B2 (en) 2012-05-10 2014-05-13 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
WO2013170142A1 (en) 2012-05-10 2013-11-14 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof

Also Published As

Publication number Publication date
PL3119793T3 (pl) 2018-07-31
BR112016021542A2 (https=) 2017-08-15
US10227371B2 (en) 2019-03-12
PT3119793T (pt) 2018-05-10
SI3119793T1 (en) 2018-06-29
EP3119793A1 (en) 2017-01-25
DK3119793T3 (en) 2018-05-22
BR112016021542B1 (pt) 2023-01-31
AU2015233583B2 (en) 2019-04-11
IL265180B (en) 2022-01-01
US20170081355A1 (en) 2017-03-23
HUE038426T2 (hu) 2018-10-29
CN106103462A (zh) 2016-11-09
WO2015140153A1 (en) 2015-09-24
IL265180A (en) 2019-05-30
CA2940902C (en) 2022-10-25
HRP20180668T1 (hr) 2018-06-15
CA2940902A1 (en) 2015-09-24
ES2668351T3 (es) 2018-05-17
EP3119793B1 (en) 2018-03-14
JP2017507994A (ja) 2017-03-23
IL247726A0 (en) 2016-11-30
AU2015233583A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
US10738038B2 (en) Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
JP2009533330A (ja) ドセタキセルの多形体およびプロセス
CN104011035A (zh) 卡巴他赛的晶型和用于制备其的方法
EA029995B1 (ru) Новая кристаллическая форма соли 1-(5-(2,4-дифторфенил)-1-((3-фторфенил)сульфонил)-4-метокси-1h-пиррол-3-ил)-n-метилметанамина
KR20160134719A (ko) 신규한 다형체 및 신규한 고체 상태의 티아쿠미신 ｂ
US20180057503A1 (en) Pharmaceutically Acceptable Salts and Polymorphic Forms of Hydrocodone Benzoic Acid Enol Ester and Processes for Making Same
EP4034256B1 (en) Solid state forms of lucerastat salts and process for preparation thereof
WO2020051014A1 (en) Processes for the preparation of tenapanor and intermediates thereof
WO2011153221A1 (en) Solid state forms of ixabepilone
ES2773502T3 (es) Nuevo polimorfo de clorhidrato de ivabradina y método para su preparación
WO2012010092A1 (zh) 一种肽类物质的晶体及其制备方法和用途
US20200283381A1 (en) Solid state forms of elafibranor
KR102150825B1 (ko) 새로운 sglt-2 억제제의 신규한 공결정
CN121021607A (zh) 环维黄杨星d盐型制品的制备方法及应用
WO2025141467A1 (en) Solid state forms of lorundrostat and process thereof
CN118063543A (zh) 一种含氮化合物的溶剂化物及其制备方法
US20150291574A1 (en) Novel polymorphs of azilsartan
BR102014014018A2 (pt) processo para a preparação de imatinibe e mesilato de imatinibe forma alfa-2 não-agulha
WO2015000165A1 (zh) 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
BR102015004857B1 (pt) Processo para a preparação de imatinibe e mesilato de imatinibe forma alfa-2 não-agulha
BRPI0708991A2 (pt) polimorfos de docetaxel e processos

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161007

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200123

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210222

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210810

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210222

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I